Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "National-Stock-Exchange"

8 News Found

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India
News | May 01, 2025

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India

The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow


Borosil Scientific debuts on stock exchange
News | June 08, 2024

Borosil Scientific debuts on stock exchange

This strategic decision will unlock significant value for our scientific and industrial products business


Cabinet approves foreign investment of up to Rs. 9,589 crore in Suven Pharmaceuticals
Policy | September 14, 2023

Cabinet approves foreign investment of up to Rs. 9,589 crore in Suven Pharmaceuticals

The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited


Sanofi India to demerge healthcare businesses
News | May 12, 2023

Sanofi India to demerge healthcare businesses

This decision will accelerate growth for both its pharma & consumer healthcare businesses in India


Briefs: Piramal Enterprises and Shilpa Medicare
News | December 02, 2022

Briefs: Piramal Enterprises and Shilpa Medicare

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval


Delivery solution provider ZIM Laboratories Limited lists on NSE
News | November 26, 2022

Delivery solution provider ZIM Laboratories Limited lists on NSE

The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.


Piramal Pharma strengthens board by inducting three new board members
People | July 11, 2022

Piramal Pharma strengthens board by inducting three new board members

The appointments will add to the well-diversified experience that currently exists on the PPL board.


Cipla gets approval from SEC to conduct Paxlovid trials
News | March 03, 2022

Cipla gets approval from SEC to conduct Paxlovid trials

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations